Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons

Pain

Volumn 107, Issue 3, 2004, Pages 267-275

  Papanastassiou, Alex M ^a   Fields, Howard L ^a   Meng, Ian D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Cannabinoid receptor agonist; Craniofacial pain; Wide dynamic range

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ISOFLURANE; RIMONABANT;

AFFERENT NERVE GROUP 1; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN STEM; CONTROLLED STUDY; ELECTROSTIMULATION; EVOKED SOMATOSENSORY RESPONSE; FACE; MALE; MECHANICAL STIMULATION; MUSCLE SPINDLE AFFERENT NERVE; NERVE CELL STIMULATION; NERVE FIBER C; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTIVE FIELD; SKIN SENSATION; SPINAL CORD NERVE CELL; TRANSCUTANEOUS NERVE STIMULATION; TRIGEMINAL NUCLEUS;

EID: 0345829178     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2003.11.009     Document Type: Article

References (61)

1. Bereiter D.A., Bereiter D.F., Hirata H. Topical cannabinoid agonist, WIN55,212-2 reduces cornea-evoked trigeminal brainstem activity in the rat. Pain. 99:2002;547-556.
2. Breivogel C.S., Griffin G., DiMarzo V., Martin B. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharm. 60:2001;155-163.
3. Buxbaum D., Sanders-Bush E., Efron D. Analgesic activity of tetrahydrocannabinol (THC) in the rat and mouse. Fed Proc. 28:1969;735.
4. Campbell F.A., Tramer M.R., Carroll D., Reynolds D.J.M., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J. 323:2001;1-8.
5. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology. 41:2001;870-877.
6. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement of mu opioid antinociception by oral delta-9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 289:1999;859-867.
7. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:1988;605-613.
8. Dickenson A.H., Le Bars D., Besson J.M. Diffuse noxious inhibitory controls (DNIC). Effects on trigeminal nucleus caudalis neurones in the rat. Brain Res. 200:1980;293-305.
9. Drew L.J., Harris J., Millns P.J., Kendall D.A., Chapman V. Activation of spinal cannabinoid 1 receptors inhibits C-fiber driven hyperexcitable neuronal responses and the [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci. 12:2000;2079-2086.
10. Dunn M., Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia. 12:1974;175.
11. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
12. Giuliani D., Ferrari F., Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res. 41:2000;47-53.
13. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
14. Henriksson B.G., Jarbe T. Cannabis-induced vocalization in the rat. J Pharm Pharmacol. 23:1971;457-458.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 11:1991;563-583.
16. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160.
17. Hohmann A.G., Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett. 252:1998;13-16.
18. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
19. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
20. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
21. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett. 257:1998;119-122.
22. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822:1999;17-25.
23. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 81:1999;575-583.
24. Hu J.W. Response properties of nociceptive and non-nociceptive neurons in the rat's trigeminal subnucleus caudalis (medullary dorsal horn) related to cutaneous and deep craniofacial afferent stimulation and modulation by diffuse noxious inhibitory controls. Pain. 41:1990;331-345.
25. Jain A.K., Ryan J.R., McMahon G.F., Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 21:1981;320S-326S.
26. Jennings E.A., Vaughan C.W., Christie M.J. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol. 534:(3):2001;805-812.
27. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain. 93:2001;303-315.
28. 1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol. 86:2001;3061-3064.
29. Khasabova I., Simone D., Seybold V. Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rat. Neuroscience. 115:2002;613-625.
30. Li J., Simone D.A., Larson A.A. Windup leads to characteristics of central sensitization. Pain. 79:1999;75-82.
31. Lichtman A.H., Smith P., Martin B.R. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain. 51:1992;19-26.
32. Mao J., Price D.D., Lu J., Keniston L., Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett. 280:2000;13-16.
33. Martin B.R., Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol Dis. 5:1998;447-461.
34. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci. 16:1996;6601-6611.
35. Martin W.J., Coffin P.O., Attias E., Balinsky M., Tsou K., Walker J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 822:1999;237-242.
36. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
37. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
38. Mendell L.M. Physiological properties of unmyelinated fiber projection to the spinal cord. Exp Neurol. 16:1966;316-332.
39. Millns P.J., Chapman V., Kendall D.A. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol. 132:2001;969-971.
40. Moss D.E., Johnson R.L. Tonic analgesic effects of delta-9- tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol. 61:1980;313-315.
41. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
42. Noyes R., Baram D.A. Cannabis analgesia. Comp Psychiatry. 15:1974;531-535.
43. Noyes R., Brunk S.F., Avery D.H., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 18:1975;84-89.
44. Noyes R., Brunk S.F., Baram D.A., Canter A. Analgesic effect of Delta-9-tetrahydrocannabinol. J Clin Pharmacol. 15:1975;139-143.
45. Palmer S., Thakur G., Makriyannis A. Cannabinergic ligands. Chem Phys Lipids. 121:2002;3-19.
46. Papanastassiou A., Meng I.D., Mitrovic I., Fields H.L. Locally applied cannabinoid agonists differentially affect nociceptive and non-nociceptive trigeminal nucleus caudalis neurons. Soc Neurosci Abstr. 2001.
47. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol. 63:2001;569-611.
48. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther. 1976;26-33.
49. Richardson J.D., Aanonsen L., Hargreaves K.M. Anti-hyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 345:1998;145-153.
50. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 76:1998;3-8.
51. Sofia R.D., Nalepa S.D., Harakel J.J., Vassar H.B. Anti-edema and analgesic properties of delta-9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther. 186:1973;646-655.
52. Strangman N.M., Walker J.M. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol. 81:1999;472-477.
53. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
54. Wall P.D., Woolf C.J. The brief and the prolonged facilitatory effects of unmyelinated afferent input on the rat spinal cord are independently influenced by periphral nerve section. Neuroscience. 17:1986;1199-1205.
55. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally- administered cannabinoids alone, and in combination with morphine in mice. J Pharmacol Exp Ther. 262:1992;10-18.
56. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther. 286:1998;1301-1308.
57. Woolf C.J. Evidence for a central component of post-injury pain hypersensitivity. Nature. 306:1983;686-688.
58. Woolf C.J. Windup and central sensitization are not equivalent. Pain. 66:1996;105-108.
59. Woolf C.J., Wall P.D. Chronic peripheral nerve section diminishes the primary afferent A-fibre mediated inhibition of rat dorsal horn neurones. Brain Res. 242:1982;77-85.
60. Woolf C.J., Wall P.D. The relative effectiveness of C primary afferent fibres of different origins in evoking a prolonged facilitation of the flexor reflex in the rat. J Neurosci. 6:1986;1433-1443.
61. Yaksh T.L. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J Clin Pharmacol. 21:1981;334S-340S.